

## Analytical Method Validation In Herbal Products: Challenges, Strategies, And Global Regulatory Guidelines

Bansi Prafulbhai Dadhaniya<sup>1</sup>, Bhoomi D Patel<sup>1\*</sup>, Sanjesh Rathi<sup>2</sup>

<sup>1</sup>\*Department of Pharmaceutical Chemistry & Quality Assurance, School of Pharmacy, Rai University, Saroda, Dholka Road, Ahmedabad, Gujarat, INDIA-382260.

<sup>2</sup> Department of Pharmaceutics, School of Pharmacy, Rai University, Saroda, Dholka Road, Ahmedabad, Gujarat, INDIA-382260

### Corresponding Author

Dr. Bhoomi D. Patel

Associate Professor & HOD Department of Pharmaceutical Chemistry & Quality Assurance, School of Pharmacy, Rai University, Saroda, Dholka Road, Ahmedabad, Gujarat, INDIA.

Email: [bhoomi.patel@raiuniversity.edu](mailto:bhoomi.patel@raiuniversity.edu)

Cite this paper as Bansi Prafulbhai Dadhaniya, Bhoomi D Patel, Sanjesh Rathi (2026) Analytical Method Validation In Herbal Products: Challenges, Strategies, And Global Regulatory Guidelines.. Journal of Neonatal Surgery, 15 (1s) 32-47

### ABSTRACT

In the fields of pharmaceutical and nutraceutical sciences, validating analytical techniques for herbal products is a challenging and dynamic task. Due to differences in plant species, growing circumstances, harvesting methods, and processing techniques, herbal formulations are naturally more varied than synthetic medications. Because of this inherent diversity, repeatability is a constant problem and the creation of uniform markers is made more difficult. Furthermore, sophisticated analytical instruments that can accurately evaluate identification, purity, potency, and stability are required due to the coexistence of several bioactive components in herbal medicines. When used alone, traditional techniques like HPLC, GC, and UV spectrophotometry are frequently insufficient, which leads researchers to turn to hyphenated and high-resolution approaches like LC-MS, NMR, and metabolomics-based profiling. Global regulatory frameworks, including as those of the US FDA, WHO, EMA, and AYUSH in India, place a strong emphasis on the necessity of scientifically proven techniques to guarantee the efficacy, safety, and quality of products. However, recommendations frequently have different standards, which makes worldwide harmonization and compliance difficult. The acceptance of herbal medicines and worldwide trade are made more difficult by this discrepancy. A comprehensive strategy that incorporates risk-based validation principles customized for herbal matrices, chemometric instrument application, reference standard utilization, and robust method development is required to overcome these obstacles. In the end, method validation for herbal medicines is not just a legal obligation; it is also a scientific necessity to protect patient safety and boost trust in conventional treatments as they become more widely used in healthcare. Innovative approaches and international collaboration to address these issues will open the door to more uniform quality standards and increased adoption of herbal remedies..

**Keywords:** Analytical method validation, Herbal products, Phytochemical standardization, Quality control, Regulatory guidelines, Chromatographic fingerprinting

### INTRODUCTION

Often referred to as botanicals, phytomedicines, or traditional remedies, herbal products hold a special position at the nexus of conventional wisdom and contemporary medical treatment. Long histories of use and a growing consumer preference for "natural" medicines are the foundations of their widespread popularity, yet the very characteristics that draw people to botanicals also provide significant analytical challenges. Herbal medicines are intricate multicomponent matrices with a phytochemical content that varies according on the species, cultivar, harvest season, soil and climate, post-harvest management, and production techniques, in contrast to single-entity synthetic pharmaceuticals (1). Unless techniques are specially created and thoroughly verified for the matrix in issue, this inherent variability makes it more difficult to choose the right analytical markers and compromises repeatability (2-4). Reliable quality control is based on method validation, which shows that an analytical procedure satisfies predetermined performance criteria for its intended use, such as robustness, linearity, sensitivity (LOD/LOQ), specificity, accuracy, precision, and stability-indicating capability (5). Recent years have seen a strengthening and harmonization of regulatory frameworks for validation, particularly through ICH Q2(R2) and

companion publications on analytical process development, which offer broad guidelines that apply to spectroscopic, chromatographic, and hyphenated procedures. However, these high-level guidelines need to be modified for herbals: regional guidance (EMA, FDA, WHO, and national authorities) and monographs and Pharmacopeial standards (e.g., Ph. Eur., USP) emphasize the necessity of taking botanical-specific concerns like contaminants, fingerprinting, and marker selection into account in any validation plan.

First, accurate quantification and interlaboratory comparability are hampered by the lack of certified reference materials or their high cost, which limits the selection and accessibility of reference standards for many natural elements (6, 7). Second, co-extracted interfering compounds and matrix effects (ion suppression/enhancement in MS; spectrum overlap in spectroscopy) can lower technique specificity, necessitating orthogonal separations, hyphenated detectors, or meticulous sample cleanliness (8, 9). Third, instead of using a single marker, many quality evaluations now use chemical fingerprinting or multicomponent assays, which increases validation complexity because it is necessary to demonstrate that numerous peaks and pattern-recognition criteria are consistent and selective across lots (10-12). Last but not least, there is still a constant possibility of adulteration and replacement, whether deliberate or unintentional, which makes strong authentication and adulterant detection crucial components of any analytical program (13, 14). Best practices have surfaced from the academic and regulatory domains to address these issues. Cross-validation is supported and complicated mixtures and unknowns are resolved with the use of orthogonal and hyphenated techniques (HPLC/UPLC-PDA, LC-MS/MS, GC-MS, NMR, and metabolomics profiling) (3, 7, 15). The use of chemometric and multivariate techniques (PCA, PLS, cluster analysis) to identify outliers, establish batch-equivalence bounds, and analyse complicated fingerprints is growing, and regulators are realizing the benefits of these methods when they are openly disclosed (16, 17). Focusing validation efforts on clinically important analytes and performance requirements is made easier by risk-based procedures that establish an Analytical Target Profile (ATP) linked to Critical Quality Attributes (CQAs) (18).

Another pillar is the development of stability-indicating methods and forced-degradation studies. To establish storage/expiry claims and show method specificity, it is essential to evaluate the behaviour of marker compounds and possible degradation products under stress conditions (heat, light, humidity, pH, and oxidation) (10, 17). Proficiency testing and interlaboratory (round-robin) studies can further establish robustness and method transferability across various equipment or laboratories, which is a crucial step when multi-site manufacturing or international trade is involved (19, 20). The process of regulatory convergence is still ongoing. Global harmonization is still hampered by disparities in acceptance criteria and the real-world implementation of chemometric or metabolomics-based approaches, despite the fact that international organizations like WHO, ICH, EDQM, EMA, and national pharmacopeia's offer guidelines and monographs that harmonize many concepts. International acceptance of herbal products would be facilitated and reliable quality assessment accelerated by cooperative efforts among regulators, industry, and academia to create validated reference materials, shared method repositories, and agreed-upon criteria for fingerprint equivalency (10).

## HERBAL PRODUCTS: CHARACTERISTICS AND QUALITY CONSIDERATIONS

Herbal products, which are made from plant ingredients, are a complicated fusion of contemporary medicine and traditional wisdom. Because of its historical medicinal usage, perceived safety, and affordability, their demand has increased globally. Because of the inherent complexity of these goods and the variation in their composition, guaranteeing quality, safety, and efficacy is still a significant difficulty despite their widespread use. Effective quality assurance requires a systematic grasp of herbal properties, standardization requirements, quality concerns, and the function of analytical validation.

### 2.1 Complexity of Herbal Products:

Several kinds of bioactive substances, such as alkaloids, flavonoids, terpenes, glycosides, phenolics, and essential oils, are inherent in the complexity of herbal products. Synergistic interactions between these molecules, as opposed to a single constituent, are frequently the cause of the therapeutic efficacy. Because of their multicomponent structure, analysis and quality control are especially difficult because different bioactive may have unique physicochemical characteristics that call for a variety of analytical methods to identify and quantify them (13, 21).

Furthermore, external factors have a significant impact on the chemical makeup of herbal items. Climate, altitude, soil composition, and geographic origin can all have a big impact on how active components are biosynthesised. Chemical variability is further influenced by plant maturity at harvest and seasonal change. Degradation or loss of bioactive components can also result from post-harvest management, which includes drying, storing, and processing techniques (11). These variances highlight how crucial thorough quality control procedures and methodical characterisation are to guaranteeing batch-to-batch consistency (22).

### 2.2 Standardization Needs:

Standardization is essential to ensuring consistent efficacy and safety of herbal products due to their complexity and diversity. As reference points for product identification, potency, and purity, standardization entails identifying and managing important phytochemical indicators. Therapeutic relevance, abundance, and analytical detectability all play a role in the

selection of suitable markers (23). Fingerprinting methods have become effective instruments for evaluating the quality of herbal products, surpassing single-marker approaches. When paired with photodiode array (PDA) or mass spectrometer (MS) detectors, chromatographic techniques like high-performance liquid chromatography (HPLC), gas chromatography (GC), and ultra-performance liquid chromatography (UPLC) provide thorough profiling of several substances. These chemical fingerprints offer a comprehensive perspective of the herbal matrix, facilitating batch comparison, adulteration detection, and verification. The ability to comprehend complicated datasets and guarantee reproducibility is further improved by recent developments in metabolomics and chemometric techniques, such as principal component analysis (PCA) and partial least squares (PLS) regression. Standardization by fingerprinting and marker measurement is essential for creating dependable, superior herbal medicines (24).

### 2.3 Quality Issues

Herbal goods often have a number of quality problems, even with best procedures. There are still serious worries about adulteration and substitution with subpar, dormant, or even hazardous plant materials. Intentional or inadvertent, these behaviours may emerge as a result of misidentification during collection or as a means of cutting production costs. Another prevalent problem is contamination with heavy metals including lead, mercury, cadmium, and arsenic, which frequently arises from contaminated soils or improper farming methods. If pesticide residues are not well managed, they can remain on plant materials and present serious health hazards. Additionally, common, especially in materials that have been inadequately dried or stored, is microbial contamination, which includes bacteria, fungus, and mycotoxins and can jeopardize both safety and therapeutic efficacy (25).

When taken as a whole, these quality problems show how urgently thorough testing including physicochemical and microbiological evaluations is required. To reduce these risks, regulatory agencies like the World Health Organization (WHO), European Medicines Agency (EMA), and U.S. Food and Drug Administration (FDA) place a strong emphasis on following good manufacturing practices (GMP), good agricultural and collection practices (GACP), and thorough quality control procedures (26, 27).

### 2.4 Role of Analytical Validation in Quality Assurance.

Validation of analytical methods is essential to guaranteeing the quality of herbal products. Validation guarantees that analytical methods yield accurate, repeatable, and dependable findings for the intended use. Specificity, accuracy, precision, linearity, robustness, stability-indicating capability, limit of detection (LOD), and limit of quantitation (LOQ) are important criteria (28, 29). The intricate matrices of herbal products require that each parameter be customized. To differentiate target phytochemicals from co-extracted substances and other contaminants, for instance, specificity is essential. In order to monitor degradation products that may occur during processing or storage, stability-indicating techniques are crucial. While linearity guarantees the method offers dependable quantification over the anticipated concentration range, precision and accuracy verify that measurements are repeatable both within and between laboratories (30).

Numerous quality assurance goals are supported by validated analytical techniques, including raw material authentication, adulteration or substitute detection, active marker measurement, contaminant monitoring, and batch-to-batch consistency verification. The integration of chromatographic, spectroscopic, and hyphenated techniques, coupled with chemometric data analysis, has evolved as a best practice for addressing the multicomponent nature of herbal products and their intrinsic variability (31-33).




Figure 1: Herbal Products: Characteristics and Quality Considerations

## Analytical Methods for Herbal Products

The foundation of quality control for herbal products is analytical method validation, which guarantees that analytical techniques are dependable, repeatable, and appropriate for their intended use. Validation is especially difficult since herbal matrices are inherently complex, necessitating techniques that can precisely measure a variety of active ingredients, identify impurities, and confirm the identity of the plant. The main ideas, methodologies, and approaches used in the verification of analytical procedures for herbal products are examined in this section (24, 34).

### Chromatographic Techniques

Chromatography is still the mainstay of herbal analysis since it makes it possible to separate, identify, and measure a variety of bioactive components in intricate matrices. Because of its accuracy, adaptability, and compatibility with a range of detectors, including mass spectrometry (MS) and photodiode arrays (PDA), high-performance liquid chromatography (HPLC) is widely used. For high-throughput screening of herbal extracts, ultra-performance liquid chromatography (UPLC) is a good option since it provides better resolution, lower solvent consumption, and quicker run times (34, 35).

For volatile substances, such as terpenes and essential oils, which are frequently found in herbal formulations, gas chromatography (GC) is very useful. When used in conjunction with detectors like mass spectrometry (GC-MS) or flame ionization (FID), GC offers excellent sensitivity and specificity for identifying trace amounts of pollutants or other small components. Chromatographic fingerprinting is becoming a common method for assessing batch-to-batch consistency and identifying adulteration because it assesses a herbal product's total chemical profile rather than its specific elements (36, 37).

### Spectroscopic Methods

Spectroscopic methods offer quick, non-destructive, and frequently high-throughput analysis of herbal materials, which is a useful addition to chromatography procedures. Ultraviolet-visible (UV-Vis) spectroscopy is frequently employed for extract screening in the early stages and to track the content of chromophoric components such as flavonoids and phenolic acids. By providing molecular-level understanding of functional groups, Fourier-transform infrared (FTIR) spectroscopy makes it possible to distinguish between genuine and tampered samples (38-40). Multiple components can be simultaneously identified and quantified without previous separation thanks to the precise structural information on metabolites provided by nuclear magnetic resonance (NMR) spectroscopy. By comparing the spectrum patterns of herbal batches to reference standards, NMR-based fingerprinting in conjunction with chemometric analysis provides reliable quality control and authentication. Despite being less precise than hyphenated methods, these spectroscopic techniques are quite helpful for quick screening and first quality assessment (41, 42).

### Hyphenated Techniques

Hyphenated approaches combine sensitive detection systems with separation procedures to improve analytical power and specificity. For herbal matrices including several bioactive chemicals, liquid chromatography-mass spectrometry (LC-MS) is perfect because it enables the simultaneous isolation and structural elucidation of complicated ingredients. Accurate quantification of low-abundance markers and contaminants is made possible by the additional sensitivity and selectivity that LC-MS/MS with tandem mass spectrometry provides (43, 44).

Essential oils and pesticide residues are two examples of volatile and semi-volatile substances that are frequently subjected to gas chromatography-mass spectrometry (GC-MS). Because of its great sensitivity, it can identify pollutants at minuscule levels that could endanger public safety. Chromatographic separation and NMR detection are combined in LC-NMR to provide comprehensive structural information for complex mixtures that are challenging to resolve using other methods. Hyphenated techniques, which are frequently used in conjunction with chemometric data analysis, offer thorough chemical fingerprints and are becoming more and more recognized as the gold standard for validating the quality of herbal products (44-46).

### DNA-based Authentication

DNA-based authentication confirms the botanical identity of raw materials, whilst chemical profiling guarantees the quality and consistency of herbal products. Short, standardized gene sections like *rbcL*, *matK*, or *ITS* are used in DNA barcoding to accurately identify plant species. The detection of adulteration, replacement, or misidentification all of which are frequent problems in commercial herbal products is where our method excels (47, 48).

A powerful tool for intricate polyherbal preparations, next-generation sequencing (NGS) enables the simultaneous identification of many species in processed or mixed herbal formulations. In addition to chemical analyses, DNA-based methods guarantee the integrity and authenticity of herbal products. A thorough validation framework is produced by combining molecular authentication with chromatographic and spectroscopic techniques, improving consumer safety and regulatory compliance (49, 50).

### Method Validation: Principles and Parameters (1000-1200 words)

This guideline presents a discussion of elements for consideration during the validation of analytical procedures included as

part of registration applications submitted within the ICH member regulatory authorities. s. Q2(R2) provides guidance and recommendations on how to 5 derive and evaluate the various validation tests for each analytical procedure. This guideline 6 serves as a collection of terms, and their definitions. These terms and definitions are meant to 7 bridge the differences that often exist between various compendia and documents of the ICH member regulatory agencies. (Guideline IH. Validation of analytical procedures Q2 (R2). ICH: Geneva, Switzerland. 2022;1.) International Conference on Harmonization (ICH) Q2(R1) provides a formal overview of the criteria required to fully validate an analytical procedure. It highlights that the purpose of any method validation is to demonstrate that it is “suitable for its intended purpose” (51).

The ICH documents define specificity as the ability to assess unequivocally the analyte in the presence of components that may be expected to be present, such as impurities, degradation products, and matrix components (52). Validated analytical methods are essential for herbal drugs because the chemical composition is complex and can vary from batch to batch. Standardized methods help control variability caused by differences in plant species, growing conditions, harvesting, and processing. To meet global regulatory requirements, authentic identification, accurate quantification of actives, and contaminant testing are required these ensure every product batch is consistent, safe, and effective. Without validated methods, claims about efficacy and safety are unreliable and risk regulatory rejection as well as loss of consumer trust (17, 53).

Analytical method validation of herbal products is necessary to provide consistent and accurate quantitation of bioactive molecules. Herbal matrices such as Ashwagandha pose special difficulties owing to their chemical heterogeneity and complexity, requiring method standardization and validation to ensure quality control. Using methods like maximizing extraction and chromatographic conditions, and compliance with worldwide regulatory standards (e.g., ICH, WHO), enables powerful validation of analytical method ultimately enhancing the safety, efficacy, and reproducibility of herbal products in international markets (54).

Method validation is a critical activity in the pharmaceutical industry that ensures an analytical procedure used for a specific test is suitable for its intended purpose. This process confirms accuracy, sensitivity, specificity, and reproducibility, which are essential requirements under Good Manufacturing Practices (GMPs). Regulatory guidelines from agencies such as the FDA, ICH, and WHO mandate that validation data must be thoroughly documented, aligning with Section 21 CFR 211.165(e) and 211.194(a), which emphasize that test methods must have established and documented performance characteristics. Before method development, relevant information like chemical structures, analyte concentration, solubility, stability, sample matrix, spectroscopic properties, and other physical and chemical characteristics of method validation lifecycle the Active Pharmaceutical Ingredient (API) and related components should be gathered to design a robust method. For example, in the herbal industry, validated HPLC methods are used to standardize complex botanical extracts, such as Ashwagandha, by quantifying multiple withanolides reliably (55, 56). This approach ensures that the analytical procedure meets regulatory standards while providing reproducible and accurate quality control for herbal products, thereby linking the principles of method validation directly to product safety and efficacy in both synthetic and herbal pharmaceuticals (57).

There are multiple key parameters for method validations like specificity to assess the analyte unequivocally without interference from other components, accuracy to closeness of test result to the true value, precision for repeatability and intermediate precision, linearity and range for direct relationship and operational scope for analyte quantification, and robustness to reliable under small deliberate variation in method parameters.

Selectivity and specificity.

Accuracy

Precision

Linear function analysis

Range

Limit of detection

Ruggedness

Robustness

This parameter evaluates the constancy of the results when internal factors (no external factors as in ruggedness) such as flow rate, column temperature, injection volume, mobile phase composition or any other variable inherent to the method of analysis are varied deliberately. It is generally not considered in most validation guidelines (58).

The application of ICH validation principles to herbal products requires careful consideration of the unique characteristics that distinguish natural products from synthetic pharmaceuticals. Accelerated timelines: Rapid development cycles require efficient validation planning and execution, while the complexity of herbal matrices demands extended validation studies to address matrix effects, extraction variability, and compound stability. The validation approach must account for the multi-component nature of herbal products, often requiring simultaneous validation of multiple analytes with different chemical

properties and concentration ranges. Method validation for herbal products frequently employs chemometric approaches to handle complex data sets and establish meaningful validation criteria for fingerprinting methods. The integration of traditional validation parameters with modern analytical technologies, including hyphenated techniques and advanced data processing methods, represents the current state of art in herbal product method validation, ensuring that validated methods can reliably support quality control and regulatory compliance for these complex natural products (59, 60).

### **Challenges in Analytical Method Validation for Herbal Products**

Any health effects of herbal medicines are caused by pharmacologically active phytochemicals contained in these medicines. External quality issues are complex, internal ones, however, can be even more challenging. Plants can synthesize a bewildering variety of phytochemicals, such as fatty acids, sterols, alkaloids, glycosides, saponins, tannins, terpenes and phenolics.<sup>48</sup> Even a single plant extract may contain hundreds of organic chemicals. For instance, more than 28 ginsenosides have been extracted from *P. ginseng*, and each might be associated with different therapeutic actions.<sup>49</sup> In mixtures of more than one herbs, the chemical compositions is even more complex. In many instances, it may be difficult to determine which ingredient is responsible for any given therapeutic effect. Depending on the growing conditions and geographic region, the composition of herbal medicines varies. A host of environmental factors, including soil, altitude, seasonal variation in temperature, atmospheric humidity, length of daylight, rainfall pattern, may affect the concentration of components in any given batch. Other factors, including genetic make-up, seeding time, use of pesticides and fertilizers, planting density also play important role.

External quality issues can be classified into three main aspects: cultivation, manufacturing, and circulation. The rigorous implementation of Good Agricultural and Collection Practices (GACP) is a crucial step towards improving the quality of herbal medicines. The WHO issued guidelines on Good Agricultural and Collection Practices (GACP) for medicinal plants in 2003; other countries or regions have also developed regional and national GACP, such as the European Union, China and Japan. The processing of herbal materials and the production of herbal products must follow Good Manufacturing Practices (GMP). Finally, the marketing of herbal medicines should also comply with the Good Supply Practices (GSP) (16).

Herbal medication products, also known as herbal medicines or phytotherapeutic products, refer to medicinal products derived from plants or plant. Quality control is a systematic approach that involves monitoring and controlling various aspects of herbal product development, manufacturing, and distribution to guarantee consistent product quality. Quality control measures are essential in any industry or organization as they play a significant role in ensuring that products or services meet the expected standards and specifications. Effective quality control measures involve evaluating processes and identifying areas for improvement. By streamlining operations, eliminating bottlenecks, and addressing inefficiencies, organizations can enhance productivity and achieve higher output levels with fewer resources (38).

Good Manufacturing Practices (GMP) guidelines are essential to the herbal industry to maintain product quality and protect consumer health. GMP for herbal products is a set of guidelines and principles that ensure the quality, safety, and consistency of herbal medicines, supplements, and other herbal products. It involves raw material sourcing and identification, facility and equipment, standard operating procedures, batch records and documentation, quality control testing, validation and qualification, stability testing, recalls and complaints, regulatory compliance, and continuous improvement. GMP also involves proper documentation, personnel training, hygiene practices, and quality control procedures to ensure consistent quality throughout the manufacturing process. GMP requires the use of high-quality, authentic, and properly identified herbal raw materials. Suppliers should be carefully selected and qualified to ensure the consistency and purity of the ingredients. GMP-compliant facilities should be designed, maintained, and operated in a manner that prevents cross-contamination, ensures cleanliness, and provides a controlled environment for manufacturing (17, 61).

## **Strategies to Overcome Validation Challenges**

### **6.1 Complexity and Variability of Herbal Matrices**

Herbal products present extraordinary complexity because they often contain hundreds of secondary metabolites, many of which vary depending on species, geography, harvest time, and processing. Unlike synthetic drugs, where a single active ingredient defines therapeutic activity, herbal formulations often rely on synergistic effects between multiple compounds. This complexity makes it difficult to select appropriate chemical markers for validation, leading to inconsistencies in analytical outcomes.

Furthermore, intra-species variability caused by environmental and genetic factors introduces batch-to-batch differences that complicate reproducibility. Even within the same species, phytochemical composition can differ drastically depending on soil nutrients, climate, and cultivation practices. Such variability often undermines efforts to establish universally accepted reference standards, hampering both quality control and regulatory harmonization (62).

### **6.2 Lack of Standardized Reference Materials**

Another critical barrier is the limited availability of certified reference materials (CRMs) for herbal compounds. Without

authenticated standards, it becomes nearly impossible to verify the accuracy of quantitative assays. Laboratories often rely on in-house references or purchase commercial standards of varying quality, which can introduce inter-laboratory discrepancies.

The absence of CRMs also limits the development of harmonized methods across regulatory agencies. This lack of consistency complicates the global exchange of herbal products, as validation results from one region may not be recognized elsewhere. Until internationally certified herbal CRMs are widely available, standardization will remain a significant challenge (63).

### 6.3 Adulteration and Contamination Risks

Adulteration whether intentional (economic gain) or unintentional (misidentification) remains a major obstacle in herbal validation. Substitution with cheaper plants, synthetic drugs, or toxic fillers not only misleads consumers but also poses safety risks. For example, cases of nephrotoxicity linked to aristolochic acid contamination highlight the severe consequences of inadequate validation.

In addition to adulteration, contamination from heavy metals, pesticides, or microbial growth further complicates quality assurance. Detecting these contaminants requires advanced analytical tools that are often unavailable in resource-limited settings. The combination of intentional adulteration and inadvertent contamination underscores the urgent need for robust, multi-layered validation strategies (64).

### 6.4 Challenges in Chromatographic Fingerprinting

Chromatographic fingerprinting (e.g., HPTLC, HPLC, GC-MS) is widely employed for herbal quality assessment, but its application faces significant hurdles. One challenge is the lack of universally accepted fingerprint libraries, which hinders cross-laboratory reproducibility. Additionally, peak overlap in complex mixtures makes it difficult to assign identity to specific bioactive constituents.

Moreover, fingerprinting methods often capture only a subset of the total phytochemical spectrum, potentially overlooking critical compounds that contribute to therapeutic effects. Standardizing fingerprinting techniques across laboratories remains a daunting task due to instrument variability, column differences, and operator expertise. These limitations highlight the need for hybrid approaches that combine chromatographic data with spectroscopic and chemometric analysis (65, 66).

### 6.5 Biological Assays: Reproducibility and Relevance

Biological assays are essential for evaluating pharmacological activity, but they face challenges in reproducibility and clinical relevance. Variability in cell culture conditions, animal models, and assay protocols can lead to inconsistent results, limiting their value in routine validation. Additionally, bioassays often focus on single pathways or endpoints, which may not capture the multi-target effects of herbal products.

Translational relevance is another issue effect observed in vitro or in animal models may not always reflect clinical outcomes. Bridging this gap requires standardizing bioassay protocols and integrating them with chemical validation tools. Only then can biological assays contribute reliably to the holistic validation of herbal medicines (67).

### 6.6 Regulatory Fragmentation Across Countries

One of the most persistent challenges is the lack of global harmonization in regulatory frameworks. Different countries classify herbal medicines variously as dietary supplements, traditional medicines, or pharmaceuticals, resulting in divergent validation requirements. For example, the U.S. FDA requires safety data but not efficacy proof for dietary supplements, whereas the European Medicines Agency emphasizes both quality and clinical evidence.

This regulatory heterogeneity creates obstacles for international trade and complicates efforts to establish global standards. Companies seeking multi-country approval must navigate complex, often contradictory guidelines, which delays market entry and increases costs. Moving toward a harmonized regulatory model is essential for overcoming these challenges and ensuring global consumer safety (68).

## Global Regulatory Guidelines on Herbal Product Validation

### 7.1 WHO Guidelines: Quality Control Methods for Medicinal Plants, Monographs

The World Health Organization (WHO) has played a foundational role in establishing frameworks for the validation and quality control of herbal medicines. Its guidelines emphasize identity, purity, and potency testing of raw plant materials, accompanied by methods to detect contamination by microbes, heavy metals, and pesticides. These recommendations are presented in WHO's *Quality Control Methods for Medicinal Plant Materials* and monographs, which provide standardized specifications for commonly used herbal products. The emphasis lies not only on chemical testing but also on morphological and histological evaluation, ensuring authenticity and preventing adulteration. Importantly, WHO promotes the concept of

"quality assurance from field to finished product," integrating good agricultural and collection practices (GACP) into the supply chain (69).

These guidelines have become widely accepted references for national authorities and pharmacopeias. They also support harmonization across regulatory agencies in developing countries where herbal products form a significant part of healthcare. However, WHO guidelines are not legally binding and rely on member states for adoption, which sometimes creates inconsistency in enforcement. This limitation underscores the importance of regional and national adaptation of WHO standards into enforceable regulations (70).

### 7.2 ICH Guidelines: Q2(R1)/Q2(R2) Validation Principles and Relevance

The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has been instrumental in setting global validation principles. ICH guideline Q2(R1), and its recent revision Q2(R2), provide a structured approach to validation of analytical methods, covering specificity, linearity, accuracy, precision, detection limit, and robustness [4]. While originally developed for synthetic drugs, these principles are now widely applied to herbal medicines, particularly in analytical method validation (28).

Applying ICH guidelines to herbal medicines presents unique challenges, as herbal extracts often contain complex mixtures of active and inactive components. For example, fingerprinting methods such as HPLC or LC-MS require validation according to ICH criteria, but issues like batch variability and synergistic interactions between constituents complicate conventional validation. The recent updates in Q2(R2) have expanded applicability to modern analytical tools, making it more relevant for herbal validation and encouraging integration of multivariate statistical methods (71).

### 7.3 USFDA Guidance: Botanical Drug Development, Quality Standards, NDA Requirements

The United States Food and Drug Administration (USFDA) has issued specific guidelines for botanical drug development, recognizing the complexity of herbal medicines. The FDA Guidance for Industry: Botanical Drug Development outlines requirements for safety, quality, and efficacy, including detailed chemical characterization and biological activity testing [6]. Unlike dietary supplements regulated under the Dietary Supplement Health and Education Act (DSHEA), botanical drugs must undergo rigorous Investigational New Drug (IND) and New Drug Application (NDA) processes to be marketed with therapeutic claims. USFDA guidelines emphasize the use of chemical markers, bioassays, and manufacturing controls to ensure consistency. Successful examples include Veregen (sinecatechins from green tea) approved for genital warts, which demonstrated the feasibility of botanical drug approvals under FDA frameworks. However, many applications fail due to inadequate standardization and lack of reproducibility, underscoring the necessity of robust validation approaches tailored to herbal complexity (72-75).

### 7.4 EMA: Guidelines for Herbal Medicinal Products, HMPC

The European Medicines Agency (EMA), through its Committee on Herbal Medicinal Products (HMPC), has established a structured framework for herbal product regulation. EMA distinguishes between well-established use, traditional use, and stand-alone applications, each with specific evidence requirements. The HMPC monographs and community herbal monographs provide detailed quality standards, including chemical identification, stability, and microbiological purity.

One of EMA's major contributions is the development of *community herbal monographs*, which summarize scientific evidence and traditional usage data, serving as reference standards for marketing authorization across EU member states. While EMA guidelines have strengthened harmonization across Europe, challenges remain in evaluating complex polyherbal formulations, where existing monographs may not capture the full therapeutic profile (76-80).

### 7.5 AYUSH (India): Pharmacopoeial Standards, Herbal Monographs, PLIM Guidelines

India's Ministry of AYUSH has developed a comprehensive regulatory framework for herbal medicines, grounded in traditional systems such as Ayurveda, Siddha, and Unani. The *Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H)* publishes official monographs that detail identity, purity, and potency parameters. The Pharmacopoeial Laboratory for Indian Medicine (PLIM) plays a crucial role in developing analytical methods and reference standards. AYUSH regulations mandate compliance with pharmacopoeial specifications, good manufacturing practices (GMP), and stability testing. Unlike EMA or FDA, AYUSH places strong emphasis on traditional usage and historical safety, but modern analytical validation is increasingly being integrated to enhance global acceptability of Indian herbal products. However, international recognition of AYUSH guidelines remains limited, creating challenges for Indian herbal medicines in export markets (81, 82).

### 7.6 Chinese Pharmacopoeia: Approaches for Traditional Chinese Medicines

The Chinese Pharmacopoeia represents one of the most advanced regulatory systems for herbal medicines. It integrates traditional knowledge with modern analytical validation, requiring fingerprint profiling, quantification of multiple markers, and bioassay testing. Herbal products must comply with strict standards on contaminants, heavy metals, and pesticide

residues.

China has also pioneered the use of DNA barcoding and metabolomics for herbal authentication, enhancing the reproducibility and transparency of quality assessments. This approach demonstrates how traditional medicine systems can adapt to cutting-edge technologies, serving as a model for global integration (83).

### 7.7 Japanese and Korean Pharmacopoeias

Japan and South Korea maintain their own pharmacopoeias, which emphasize standardization of traditional herbal medicines such as Kampo and Hanbang. The Japanese Pharmacopoeia requires detailed descriptions of identity, purity, and potency tests, often combining traditional organoleptic evaluation with modern chromatographic techniques. Similarly, the Korean Pharmacopoeia integrates advanced analytical tools like HPLC and DNA sequencing into its validation framework.

Both systems illustrate how East Asian regulatory frameworks maintain cultural heritage while adopting global scientific standards. However, their guidelines are often region-specific, limiting global harmonization unless translated into common international standards (84).

### 7.8 Comparative Analysis of Global Guidelines

Comparing global frameworks reveals both convergence and divergence. WHO guidelines serve as the universal foundation, but their non-binding nature leads to varied national implementations. EMA and FDA provide the most rigorous and science-driven pathways, while AYUSH, ChP, JP, and KP emphasize traditional knowledge alongside modern testing. This divergence results in challenges for cross-border recognition of herbal products. For instance, a product validated under AYUSH standards may not meet FDA or EMA requirements, limiting its global market access. Thus, there is a pressing need for harmonization of validation principles, potentially through ICH expansion to herbal medicines or through joint WHO-ICH collaborations (85).

### 7.9 Case Studies of Herbal Drug Approvals: Successes and Failures

Several case studies illustrate the impact of regulatory frameworks on herbal drug approvals. In the United States, *Veregen*® succeeded under FDA guidelines by demonstrating consistent chemical and biological activity. In Europe, EMA approval of traditional herbal medicines such as *Ivy leaf extracts* for cough relief highlights the role of community herbal monographs. Conversely, numerous applications have failed due to lack of reproducible standardization, inadequate marker selection, or insufficient clinical evidence. These examples underscore the dual challenge of balancing traditional evidence with modern validation. They also emphasize the need for global convergence in standards to ensure that herbal medicines can be consistently validated and recognized across markets. Without harmonization, innovations in herbal therapeutics risk being confined to regional markets, limiting their broader healthcare impact (86, 87).

## Future Perspectives in Analytical Validation of Herbal Products

### 8.1 Advances in Analytical Technology: High-Resolution MS, NMR Metabolomics, Multi-Omics Integration

Recent years have seen dramatic advances in analytical technologies that are reshaping herbal product validation. High-resolution mass spectrometry (HR-MS) offers unprecedented accuracy in detecting phytochemicals at trace levels, enabling both qualitative and quantitative profiling of complex herbal mixtures. In parallel, nuclear magnetic resonance (NMR) metabolomics is increasingly being used for untargeted fingerprinting, providing holistic snapshots of metabolite compositions without the need for extensive sample preparation. These technologies, when integrated into multi-omics strategies, allow researchers to map chemical, genomic, proteomic, and metabolomic data, yielding powerful insights into the molecular basis of herbal efficacy.

The integration of omics data not only enhances quality control but also facilitates mechanistic understanding of herbal pharmacology. For instance, combining metabolomics with transcriptomics can reveal how specific compounds regulate gene expression, supporting both safety assessments and potency evaluations. These innovations mark a transition from single-marker validation to systems-level approaches, a direction that is likely to define the next generation of herbal standardization (88-90).

### 8.2 AI and Machine Learning for Data Analysis

Artificial intelligence (AI) and machine learning (ML) are becoming critical tools for managing the massive datasets generated by modern analytical technologies. In herbal validation, AI can process complex chromatographic and spectroscopic fingerprints, identify subtle patterns, and classify authentic versus adulterated products with high accuracy [4]. ML algorithms have already demonstrated superior performance in predicting bioactivity from chemical composition, allowing researchers to design quality benchmarks beyond simple chemical markers. Importantly, AI offers predictive capabilities that can anticipate stability issues, contamination risks, or even therapeutic outcomes based on compositional signatures. By automating pattern recognition and anomaly detection, AI reduces human error and accelerates decision-making in quality control laboratories. The integration of AI with HR-MS and NMR platforms will likely lead to “intelligent laboratories” that continuously refine validation models through iterative learning, revolutionizing herbal product QA

systems (91-94).

### 8.3 Blockchain and Digital Traceability for Supply Chain Quality Assurance

One of the persistent challenges in herbal product validation is ensuring supply chain transparency. Blockchain technology offers a tamper-proof digital ledger that can track herbal products from cultivation to final formulation, ensuring authenticity and traceability. Each transaction, from raw material collection to distribution, is securely recorded, reducing risks of adulteration and fraud.

When combined with digital tools such as QR codes and IoT sensors, blockchain can provide real-time data on product origin, storage conditions, and transportation integrity. This approach not only enhances consumer trust but also supports regulatory compliance by offering verifiable documentation. As global markets demand higher accountability, blockchain-enabled traceability will become a cornerstone of herbal quality assurance (95-97).

### 8.4 Personalized Herbal Medicine and Validation Needs

With the growing recognition of inter-individual variability in drug response, the concept of personalized herbal medicine is gaining momentum. Genetic differences, gut microbiome diversity, and metabolic variability all influence how patients respond to herbal therapies. Validation strategies must therefore adapt to capture this complexity, moving beyond population-level averages to individualized quality standards. Personalized validation could involve tailoring chemical marker profiles to specific patient subgroups or integrating biomarkers of response into QA processes. Advances in pharmacogenomics and digital health monitoring tools make such approaches feasible. However, this shift poses new challenges for regulators, who must balance flexibility with rigorous scientific validation to ensure safety and efficacy at an individual level (98).

### 8.5 Towards Global Harmonization of Guidelines

The globalization of herbal medicine markets underscores the urgent need for harmonized validation standards. Currently, variations among WHO, FDA, EMA, AYUSH, ChP, and JP frameworks create barriers to international trade and complicate regulatory approval. A unified set of guidelines, possibly under the ICH umbrella, would streamline validation requirements, reduce duplication of effort, and facilitate mutual recognition of quality assessments. Efforts toward harmonization are already underway, with WHO collaborating with regional agencies and ICH expanding its scope to biologics and potentially herbal medicines. Achieving consensus, however, requires reconciling traditional knowledge systems with evidence-based pharmacology, a challenge that demands both scientific diplomacy and political will (99, 100).

### 8.6 Sustainable and Ethical Sourcing with Quality Assurance Integration

Future validation strategies must also address the sustainability and ethics of herbal sourcing. Overharvesting, habitat destruction, and exploitation of local communities threaten both biodiversity and the long-term viability of herbal medicine supply chains. Incorporating sustainability metrics into validation such as sourcing certifications, ecological footprint assessments, and fair-trade compliance will be essential for responsible herbal medicine development. Integrating these criteria with analytical QA tools ensures that products meet not only chemical and biological standards but also ethical and ecological benchmarks. Such holistic validation frameworks resonate with consumer demand for sustainable healthcare and align with global policy goals like the United Nations Sustainable Development Goals (SDGs). Ultimately, sustainable sourcing linked with rigorous QA will safeguard both human health and environmental integrity in the future of herbal medicines (101-105).

## Discussion

Different from validation in synthetic pharmaceuticals, analytical technique validation in herbal products entails a complicated interplay between scientific, technological, and regulatory issues. Herbal treatments contain a variety of phytochemicals, including alkaloids, flavonoids, terpenes, saponins, glycosides, and phenolic compounds, in contrast to synthetic pharmaceuticals that only have one active ingredient. Each element may have an impact on safety, stability, and therapeutic activity. Species, genetic composition, location, soil type, climate, harvesting period, and post-harvest procedures like drying and extraction all affect the composition of these chemicals. Because of this inherent unpredictability, validation is difficult and analytical consistency and reproducibility are complicated. To guarantee that herbal medications are safe, efficacious, and of consistently high quality throughout many production batches, it is crucial to establish trustworthy analytical techniques that take this variability into account.

Validation of analytical methods in herbal products is different from validation in synthetic pharmaceuticals since it entails a complex interplay of scientific, technological, and regulatory elements. Several phytochemicals, including alkaloids, flavonoids, terpenes, saponins, glycosides, and phenolic compounds, are present in herbal remedies as opposed to synthetic medications that only include one active ingredient. Every element could affect safety, stability, and therapeutic activity. Geographical location, soil type, climate, species, genetic makeup, harvesting period, and post-harvest procedures like drying and extraction all affect the composition of these chemicals. Analytical consistency and reproducibility are complicated by this inherent heterogeneity, which makes validation a difficult undertaking. It is crucial to develop trustworthy analytical techniques that take this variability into consideration in order to guarantee the safety, efficacy, and consistently excellent

quality of herbal medications throughout various production batches.

Whereas WHO concentrates on more general safety and quality principles, EMA prioritizes botanical identification, contaminant analysis, and marker-based standardization. In contrast, AYUSH guidelines combine contemporary analytical demands with ancient knowledge. These variations highlight the necessity of worldwide validation protocol harmonization. International trade, regulatory compliance, and customer trust would all be enhanced by a single system. Because they are accessible and reasonably priced, traditional methods like HPLC, GC, and UV-visible spectrophotometry are still often employed. However, because they are not always able to differentiate between several active substances with different pharmacological characteristics, they frequently fall short in resolving the complexity of herbal mixes.

For example, UV spectrophotometry lacks selectivity for particular chemicals but may estimate the total amount of flavonoids or phenols. In a similar vein, GC is effective with volatile components such as essential oils but ineffective with polar or heat-sensitive compounds. As a result, the usage of sophisticated analytical techniques including LC-MS, NMR spectroscopy, and metabolomics profiling is growing. These methods enable the simultaneous detection and measurement of several phytochemicals due to their excellent specificity, sensitivity, and resolution. Because it captures the complete chemical profile rather than concentrating on individual substances, chemical fingerprinting has become a successful method for evaluating quality and more properly reflects the synergistic nature of herbal medicines.

Using more sophisticated techniques creates new validation problems. Costly infrastructure, knowledgeable analyzers, and cautious sample processing are necessary for instruments such as LC-MS and NMR. Matrix effects that impede detection and quantification are common in herbal matrices. Complex botanical systems require a diverse interpretation of validation metrics, including robustness, LOD, LOQ, specificity, accuracy, and precision. If additional active ingredients vary from batch to batch, confirming the correctness of a particular marker might not accurately reflect overall quality. A risk-based validation strategy is therefore necessary, concentrating on pollutants such heavy metals, herbicides, and microorganisms that have a direct impact on safety and efficacy as well as crucial quality qualities like important bioactive concentrations.

Complex herbal datasets are increasingly being handled using chemometric techniques, which integrate statistical analysis with chromatographic or spectrum data. They aid in determining batch-to-batch uniformity and distinguishing authentic products from those that have been tampered with. Finding trustworthy reference standards is still a significant challenge, though. Many phytochemicals must be extracted from plant materials using time-consuming and costly procedures because they are not commercially available. It is necessary to confirm their stability in terms of light, temperature, and humidity, even if they are available. Relative response factors, surrogate standards, and inter-laboratory certified secondary references are alternatives. Chemometric-supported chromatographic fingerprinting ensures general quality assessment and lessens reliance on specific markers.

The validation procedure is made more difficult by regulatory diversity. While dietary supplements adhere to the more accommodating DSHEA framework, prescription botanical medications are subject to stricter US FDA regulations under its Botanical Drug Development Guidance. While WHO concentrates on general validation principles, the EMA requires comprehensive documentation of identification, purity, and stability data. AYUSH combines modern testing techniques with conventional recipes. In order to satisfy different regional expectations, manufacturers who export internationally frequently need to do additional validation tests. The necessity of creating unified international standards that eliminate redundancy while maintaining quality and safety is highlighted by the fact that this duplication raises costs and development time.

Future development necessitates a methodical and cooperative approach. Pharmacopeial models used in the validation of synthetic drugs may be modeled by the establishment of standardized reference materials for major medicinal plants through international partnerships. Chemical characterization will be strengthened and batch uniformity will be guaranteed by integrating high-resolution analytical methods such as LC-MS, quantitative NMR, and metabolomics into quality control. Chemometric techniques can be used more widely to improve product authenticity, identify adulteration, and track shelf-life stability. By combining these developments, herbal research will be able to overcome analytical obstacles and improve scientific dependability while bridging the gap between traditional knowledge and contemporary analytical rigor.

It is still essential that validation guidelines be harmonized globally. Internationally accepted monographs and validation criteria for herbal medicines could be produced through cooperation under agencies like the WHO or through frameworks akin to the ICH. These initiatives would increase public trust in herbal remedies, facilitate compliance, and advance fair trade. To sum up, analytical technique validation in herbal products is essential to guaranteeing efficacy, safety, and quality and goes beyond a regulatory formality. Due to the intricacy of herbal matrices, advanced, risk-based analytical techniques backed by technological advancement and global collaboration are required. A unified strategy will support consumer confidence, scientific legitimacy, and the long-term incorporation of herbal remedies into contemporary healthcare systems...

## REFERENCES

1. Hosbas Coskun S, Wise SA, Kuszak AJ. The Importance of Reference Materials and Method Validation for Advancing Research on the Health Effects of Dietary Supplements and Other Natural Products. *Frontiers in nutrition*. 2021;8:786261.
2. Seo CS, Shin HK. Quality assessment of traditional herbal formula, Hyeonggaeyeongyo-tang through simultaneous determination of twenty marker components by HPLC-PDA and LC-MS/MS. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*. 2020;28(4):427-39.
3. Pratiwi R, Dipadharma RHF, Prayugo IJ, Layandro OA. Recent Analytical Method for Detection of Chemical Adulterants in Herbal Medicine. 2021;26(21):6606.
4. van Breemen RB. Development of Safe and Effective Botanical Dietary Supplements. *Journal of medicinal chemistry*. 2015;58(21):8360-72.
5. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs-A review. *Journal of pharmaceutical analysis*. 2014;4(3):159-65.
6. Gafner S, Blumenthal M, Foster S, Cardellina JH, 2nd, Khan IA, Upton R. Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods for Authenticating Herbal Dietary and Food Ingredients and Supplements. *Journal of natural products*. 2023;86(2):460-72.
7. An YL, Li JY, Wei WL, Li Y, Zhang JQ, Yao CL, et al. An automatic LC-MS/MS data analysis workflow for herbal compound annotation with AutoAnnotator: A case study of ten botanical origins of *Fritillaria* species. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2024;135:156193.
8. Abraham EJ, Kellogg JJ. Chemometric-Guided Approaches for Profiling and Authenticating Botanical Materials. *Frontiers in nutrition*. 2021;8:780228.
9. Saberi N, Akhgari M, Bahmanabadi L, Bazmi E, Mousavi Z. Determination of synthetic pharmaceutical adulterants in herbal weight gain supplements sold in herb shops, Tehran, Iran. *Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences*. 2018;26(2):117-27.
10. Seo CS, Shin HK. Simultaneous Analysis for Quality Control of Traditional Herbal Medicine, Gungha-Tang, Using Liquid Chromatography-Tandem Mass Spectrometry. *Molecules (Basel, Switzerland)*. 2022;27(4).
11. Pratiwi R, Dipadharma RHF, Prayugo IJ, Layandro OA. Recent Analytical Method for Detection of Chemical Adulterants in Herbal Medicine. *Molecules (Basel, Switzerland)*. 2021;26(21).
12. Sarma N, Upton R, Rose U, Guo D-a, Marles R, Khan I, et al. Pharmacopeial Standards for the Quality Control of Botanical Dietary Supplements in the United States. *Journal of Dietary Supplements*. 2021;20:1-20.
13. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Frontiers in pharmacology*. 2014;4:177.
14. Habibi P, Shi Y, Fatima Grossi-de-Sa M, Khan I. Plants as Sources of Natural and Recombinant Antimalaria Agents. *Molecular biotechnology*. 2022;64(11):1177-97.
15. Indrayanto G. The importance of method validation in herbal drug research. *Journal of pharmaceutical and biomedical analysis*. 2022;214:114735.
16. Zhang J, Wider B, Shang H, Li X, Ernst E. Quality of herbal medicines: challenges and solutions. *Complementary therapies in medicine*. 2012;20(1-2):100-6.
17. Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Frontiers in pharmacology*. 2023;14:1265178.
18. Fitzgerald M, Heinrich M, Booker A. Medicinal Plant Analysis: A Historical and Regional Discussion of Emergent Complex Techniques. *Frontiers in pharmacology*. 2019;10:1480.
19. Parveen A, Parveen B, Parveen R, Ahmad S. Challenges and guidelines for clinical trial of herbal drugs. *Journal of pharmacy & bioallied sciences*. 2015;7(4):329-33.
20. Zhou GL, Su SL, Yu L, Shang EX, Hua YQ, Yu H, et al. Exploring the liver toxicity mechanism of *Tripterygium wilfordii* extract based on metabolomics, network pharmacological analysis and experimental validation. *Journal of ethnopharmacology*. 2025;337(Pt 2):118888.
21. Wang Y, Dacosta C, Wang W, Zhou Z, Liu M, Bao Y. Synergy between sulforaphane and selenium in protection against oxidative damage in colonic CCD841 cells. *Nutrition research (New York, NY)*. 2015;35(7):610-7.
22. Choudhury A, Singh PA, Bajwa N, Dash S, Bisht P. Pharmacovigilance of herbal medicines: Concerns and future prospects. *Journal of ethnopharmacology*. 2023;309:116383.
23. Liu J, He C, Tang Y, Liu W, Xu Y, Li Z, et al. A review of *Cremastra appendiculata* (D. Don) Makino as a traditional herbal medicine and its main components. *Journal of ethnopharmacology*. 2021;279:114357.
24. Noviana E, Indrayanto G, Rohman A. Advances in Fingerprint Analysis for Standardization and Quality Control of Herbal Medicines. *Frontiers in pharmacology*. 2022;13:853023.
25. Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. *European journal of clinical pharmacology*. 2013;69(3):295-307.

26. Luo L, Wang B, Jiang J, Fitzgerald M, Huang Q, Yu Z, et al. Heavy Metal Contaminations in Herbal Medicines: Determination, Comprehensive Risk Assessments, and Solutions. *Frontiers in pharmacology*. 2020;11:595335.
27. Opuni KFM, Kretchy JP, Agyabeng K, Boadu JA, Adanu T, Ankamah S, et al. Contamination of herbal medicinal products in low-and-middle-income countries: A systematic review. *Heliyon*. 2023;9(9):e19370.
28. Cassidy B, Bloomingdale T, Carmody J. Navigating ICH Q2(R2) compliance in analytical method validation: A gap analysis toolkit to streamline risk assessment and change management. *Journal of pharmaceutical sciences*. 2025;114(6):103749.
29. Verstraete J, Kiekens F, Strobbe S, De Steur H, Gellynck X, Van Der Straeten D, et al. Clinical determination of folates: recent analytical strategies and challenges. *Analytical and bioanalytical chemistry*. 2019;411(19):4383-99.
30. Rao W, Li L, Zhang C, Zheng J, Fan X, Luan B, et al. Development and validation of a stability-indicating RP-HPLC method for the determination of fifteen impurities in rivaroxaban. *Journal of pharmaceutical and biomedical analysis*. 2023;228:115325.
31. Cui D, Li Y, Lian M, Yang F, Meng Q. Development of a simple and stability-indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process. *The Analyst*. 2011;136(15):3149-56.
32. Krishnaiah C, Vishnu Murthy M, Kumar R, Mukkanti K. Development of a stability-indicating UPLC method for determining olanzapine and its associated degradation products present in active pharmaceutical ingredients and pharmaceutical dosage forms. *Journal of pharmaceutical and biomedical analysis*. 2011;54(4):667-73.
33. Pydimarry SP, Cholleti VK, Vangala RR. Stability-indicating UPLC method for determining related substances and degradants in dronedarone. *Journal of chromatographic science*. 2014;52(7):666-75.
34. Shi ZQ, Song DF, Li RQ, Yang H, Qi LW, Xin GZ, et al. Identification of effective combinatorial markers for quality standardization of herbal medicines. *Journal of chromatography A*. 2014;1345:78-85.
35. Guo L, Duan L, Dou LL, Liu LL, Yang H, Liu EH, et al. Quality standardization of herbal medicines using effective compounds combination as labeled constituents. *Journal of pharmaceutical and biomedical analysis*. 2016;129:320-31.
36. Dursunoğlu B, Yuca H, Güvenalp Z, Gözcü S, Yilmaz B. Simultaneous Determination of Arbutin and Hydroquinone in Different Herbal Slimming Products Using Gas Chromatography-mass Spectrometry. *Turkish journal of pharmaceutical sciences*. 2018;15(3):298-303.
37. Jurica K, Karačoni IB, Šegan S, Opsenica DM, Kremer D. Quantitative analysis of arbutin and hydroquinone in strawberry tree (*Arbutus unedo* L., Ericaceae) leaves by gas chromatography-mass spectrometry. *Arhiv za higijenu rada i toksikologiju*. 2015;66(3):197-202.
38. Martin AR. Spectroscopic methods in biology, with application to neurophysiology. *Advances in biological and medical physics*. 1973;14:225-84.
39. Sasidharan S, Chen Y, Saravanan D, Sundram KM, Yoga Latha L. Extraction, isolation and characterization of bioactive compounds from plants' extracts. *African journal of traditional, complementary, and alternative medicines : AJTCAM*. 2011;8(1):1-10.
40. Ong ES. Extraction methods and chemical standardization of botanicals and herbal preparations. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2004;812(1-2):23-33.
41. Riswanto FDO, Windarsih A, Lukitaningsih E, Rafi M, Fadzilah NA, Rohman A. Metabolite Fingerprinting Based on (1)H-NMR Spectroscopy and Liquid Chromatography for the Authentication of Herbal Products. *Molecules (Basel, Switzerland)*. 2022;27(4).
42. Liu C, Zuo Z, Xu F, Wang Y. Authentication of Herbal Medicines Based on Modern Analytical Technology Combined with Chemometrics Approach: A Review. *Critical reviews in analytical chemistry*. 2023;53(7):1393-418.
43. Sdrigotti N, Collard M, Purcaro G. Evolution of hyphenated techniques for mineral oil analysis in food. *Journal of separation science*. 2021;44(1):464-82.
44. Wagner M, Oellig C. Screening for mineral oil saturated and aromatic hydrocarbons in paper and cardboard directly by planar solid phase extraction and by its coupling to gas chromatography. *Journal of chromatography A*. 2019;1588:48-57.
45. Wagner M, Oellig C. Screening for mineral oil hydrocarbons in vegetable oils by silver ion-planar solid phase extraction. *Journal of chromatography A*. 2022;1662:462732.
46. García-Cicourel AR, van de Velde B, Roskam G, Janssen HG. Supercritical fluid chromatography as a rapid single-step method for the determination of mineral oil saturated and aromatic hydrocarbons in purified mineral oils for food and cosmetics applications. *Journal of chromatography A*. 2020;1614:460713.
47. Khalil I, Hashem A, Nath AR, Muhd Julkapli N, Yehye WA, Basirun WJ. DNA/Nano based advanced genetic detection tools for authentication of species: Strategies, prospects and limitations. *Molecular and cellular probes*. 2021;59:101758.
48. Campuzano S, Ruiz-Valdepeñas Montiel V, Serafín V, Yáñez-Sedeño P, Pingarrón JM. Cutting-Edge Advances in Electrochemical Affinity Biosensing at Different Molecular Level of Emerging Food Allergens and Adulterants. *Biosensors*. 2020;10(2).

49. Georget M, Pisan E. [Next Generation Sequencing (NGS) for beginners]. *Revue des maladies respiratoires*. 2023;40(4):345-58.
50. Slatko BE, Gardner AF, Ausubel FM. Overview of Next-Generation Sequencing Technologies. *Current protocols in molecular biology*. 2018;122(1):e59.
51. Patel R, Purohit S, Solanki R, Khunt D, Patel C, Patel R, et al. Development and validation of an analytical method for trace-level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed-dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry. *Rapid communications in mass spectrometry : RCM*. 2023;37(8):e9488.
52. Pum J. A practical guide to validation and verification of analytical methods in the clinical laboratory. *Advances in clinical chemistry*. 2019;90:215-81.
53. Abeillé A, Hemforth B, Winkel E, Gibson E. Extraction from subjects: Differences in acceptability depend on the discourse function of the construction. *Cognition*. 2020;204:104293.
54. Gururani R, Patel S, Yaduvanshi N, Dwivedi J, Paliwal S, Sharma S. *Tylophora indica* (Burm. f.) Merr.: An insight into phytochemistry and pharmacology. *Journal of ethnopharmacology*. 2020;262:113122.
55. Srinivasan M, Gangurde A, Chandane AY, Tagalpallewar A, Pawar A, Baheti AM. Integrating network pharmacology and in silico analysis deciphers Withaferin-A's anti-breast cancer potential via hedgehog pathway and target network interplay. *Briefings in bioinformatics*. 2024;25(2).
56. Kumar S, Singh R, Gajbhiye N, Dhanani T. Extraction Optimization for Phenolic- and Withanolide-Rich Fractions from *Withania somnifera* Roots: Identification and Quantification of Withaferin A, 12-Deoxywithastromonolide, and Withanolide A in Plant Materials and Marketed Formulations Using a Reversed-Phase HPLC-Photodiode Array Detection Method. *Journal of AOAC International*. 2018;101(6):1773-80.
57. Zellner L, Wierer M, Himmelsbach M, Schatzmann B, Thalhamer B, Klampfl CW. Determination of Withanolides and Withanosides in Ashwagandha Based Products Using HPLC-Drift-Tube-Ion-Mobility Quadrupole Time-of-Flight Mass Spectrometry. *Electrophoresis*. 2025;46(5-6):340-6.
58. Araujo P. Key aspects of analytical method validation and linearity evaluation. *Journal of chromatography B, Analytical technologies in the biomedical and life sciences*. 2009;877(23):2224-34.
59. Balkrishna A, Joshi M, Tomer M, Verma S, Gujral S, Mulay VP, et al. Identification, Validation and Standardization of Bioactive Molecules Using UPLC/MS-QToF, UHPLC and HPTLC in Divya-Denguenil-Vati: A Penta-Herbal Formulation for Dengue Fever. *Chromatographia*. 2022;85(9):831-50.
60. Balkrishna A, Verma S, Sharma P, Tomer M, Srivastava J, Varshney A. Comprehensive and Rapid Quality Evaluation Method for the Ayurvedic Medicine Divya-Swasari-Vati Using Two Analytical Techniques: UPLC/QToF MS and HPLC-DAD. *Pharmaceuticals (Basel, Switzerland)*. 2021;14(4).
61. Balkrishna A, Sharma P, Joshi M, Srivastava J, Varshney A. Development and validation of a rapid high-performance thin-layer chromatographic method for quantification of gallic acid, cinnamic acid, piperine, eugenol, and glycyrrhizin in Divya-Swasari-Vati, an ayurvedic medicine for respiratory ailments. *Journal of separation science*. 2021;44(16):3146-57.
62. Jalil B, Heinrich M. Pharmaceutical quality of herbal medicinal products and dietary supplements - a case study with oral solid formulations containing *Lavandula* species. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*. 2025;208:107042.
63. Trapmann S, Linsinger TPJ, Koeber R. Certified reference materials for GMO analysis-more than 25 years of GMO CRM production at EC JRC. *Analytical and bioanalytical chemistry*. 2025;417(12):2387-403.
64. Rajpoot M, Bhattacharya R, Sharma S, Gupta S, Sharma V, Sharma AK. Melamine contamination and associated health risks: Gut microbiota does make a difference. *Biotechnology and applied biochemistry*. 2021;68(6):1271-80.
65. Cuadros-Rodríguez L, Ortega-Gavilán F, Martín-Torres S, Arroyo-Cerezo A, Jiménez-Carvelo AM. Chromatographic Fingerprinting and Food Identity/Quality: Potentials and Challenges. *Journal of agricultural and food chemistry*. 2021;69(48):14428-34.
66. Cuadros-Rodríguez L, Ruiz-Samblás C, Valverde-Som L, Pérez-Castaño E, González-Casado A. Chromatographic fingerprinting: An innovative approach for food 'identification' and food authentication - A tutorial. *Analytica chimica acta*. 2016;909:9-23.
67. O'Neill F, McLoughlin E, Riwanto M, Manz J, Adler A, Sutill E, et al. Reproducibility and biological variability of HDL's vascular functional assays. *Atherosclerosis*. 2015;241(2):588-94.
68. Townsend BA, Sihlahla I, Naidoo M, Naidoo S, Donnelly DL, Thaldar DW. Mapping the regulatory landscape of AI in healthcare in Africa. *Frontiers in pharmacology*. 2023;14:1214422.
69. Mykhailenko O, Buydin Y, Ivanauskas L, Krechun A, Georgiyants V. Innovative GACP Approaches for Obtaining the Quality Iris hybrida Leaves for the Pharmaceutical Industry. *Chemistry & biodiversity*. 2022;19(4):e202200149.
70. Gerschler S, Neumann N, Schultze N, Guenther S, Schulze C. Quality parameters for the medicinal plant *Drosera rotundifolia* L.: A new approach with established techniques. *Archiv der Pharmazie*. 2024;357(1):e2300436.

71. Eberle M, Wasylenko JT, Kostelac D, Kiehna S, Schellinger A, Zhang Z, et al. A Modern Framework for Analytical Procedure Development and Lifecycle Management Based on ICH Q14 Principles. *Analytical chemistry*. 2025;97(1):12-21.
72. Sudsakorn S, Bahadduri P, Fretland J, Lu C. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists. *Current drug metabolism*. 2020;21(6):403-26.
73. Bidwell J, Whelply K, Shepard S, Hariadi J. A Contextual Inquiry: FDA Investigational New Drug Clinical Review. *AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science*. 2021;2021:122-31.
74. Holbein ME, Berglund JP, Weatherwax K, Gerber DE, Adamo JE. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation? *Clinical and translational science*. 2015;8(5):526-32.
75. Bateman-House A, Robertson CT. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward. *JAMA internal medicine*. 2018;178(3):321-2.
76. Pagani E, Ropke CD, Soares CM, Perez SAC, Benevides PJC, Barbosa BS, et al. Technology Readiness Level Roadmap for Developing Innovative Herbal Medicinal Products. *Pharmaceuticals (Basel, Switzerland)*. 2024;17(6).
77. Qu L, Zou W, Wang Y, Wang M. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2018;42:219-25.
78. Qu L, Li X, Xiong Y, Wang Z, Zhou Y, Zou W, et al. Opportunities and hurdles to European market access for multi-herbal traditional Chinese medicine products: An analysis of EU regulations for combination herbal medicinal products. *Pharmacological research*. 2022;186:106528.
79. Xiong Y, Li M, Sun P, Liang W, Hornbeck RG, Che X, et al. Market access for Chinese herbal medicinal products in Europe-A ten-year review of relevant products, policies, and challenges. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2022;103:154237.
80. Qu LP, Zhang XQ, Xiong Y, Wang YT, Zou WJ. [Analysis of difficult problems on European Union laws and regulations of traditional herbal medicinal products]. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica*. 2017;42(20):4040-4.
81. Muthappan S, Elumalai R, Shanmugasundaram N, Johnraja N, Prasath H, Ambigadoss P, et al. AYUSH digital initiatives: Harnessing the power of digital technology for India's traditional medical systems. *Journal of Ayurveda and integrative medicine*. 2022;13(2):100498.
82. Muthappan S, Bagepally BS, Ponnaiah M. Promoting health economic evaluation studies in the AYUSH system of medicine: the need of the hour. *International journal of technology assessment in health care*. 2021;37(1):e82.
83. Leong F, Hua X, Wang M, Chen T, Song Y, Tu P, et al. Quality standard of traditional Chinese medicines: comparison between European Pharmacopoeia and Chinese Pharmacopoeia and recent advances. *Chinese medicine*. 2020;15:76.
84. Liao B, Hu H, Xiao S, Zhou G, Sun W, Chu Y, et al. Global Pharmacopoeia Genome Database is an integrated and mineable genomic database for traditional medicines derived from eight international pharmacopoeias. *Science China Life sciences*. 2022;65(4):809-17.
85. Park JH, Fernando K, Park YH, Park EO. Global perspectives on bipolar disorder treatment: in-depth comparative analysis of international guidelines for medication selection. *BJPsych open*. 2024;10(3):e75.
86. Abramovits W, Gupta AK. Veregen (sinecatechins ointment) 15%. *Skinmed*. 2010;8(1):46-9.
87. Veregen: a botanical for treatment of genital warts. *The Medical letter on drugs and therapeutics*. 2008;50(1280):15-6.
88. Kamal S, Malik S, Batool F, Rehman K, Akash MSH. Metabolomics of heavy metal exposure. *Advances in clinical chemistry*. 2025;128:109-54.
89. Sahana S, Sarkar J, Mandal S, Chatterjee I, Dhar S, Datta S, et al. Multi-omics approaches: transforming the landscape of natural product isolation. *Functional & integrative genomics*. 2025;25(1):132.
90. Amin A, Zaman W, Park S. Harnessing Multi-Omics and Predictive Modeling for Climate-Resilient Crop Breeding: From Genomes to Fields. *Genes*. 2025;16(7).
91. Theodosiou AA, Read RC. Artificial intelligence, machine learning and deep learning: Potential resources for the infection clinician. *The Journal of infection*. 2023;87(4):287-94.
92. Praveen SV, Deepika R. Exploring the perspective of infection clinicians on the integration of Large Language Models (LLMs) in clinical practice: A deep learning study in healthcare. *The Journal of infection*. 2023;87(4):e68-e9.
93. Abd-Alrazaq A, AlSaad R, Alhuwail D, Ahmed A, Healy PM, Latifi S, et al. Large Language Models in Medical Education: Opportunities, Challenges, and Future Directions. *JMIR medical education*. 2023;9:e48291.
94. Claman D, Sezgin E. Artificial Intelligence in Dental Education: Opportunities and Challenges of Large Language Models and Multimodal Foundation Models. *JMIR medical education*. 2024;10:e52346.
95. Uddin M, Salah K, Jayaraman R, Pesic S, Ellahham S. Blockchain for drug traceability: Architectures and open challenges. *Health informatics journal*. 2021;27(2):14604582211011228.

96. Akram W, Joshi R, Haider T, Sharma P, Jain V, Garud N, et al. Blockchain technology: A potential tool for the management of pharma supply chain. *Research in social & administrative pharmacy : RSAP*. 2024;20(6):156-64.
97. Kumar D, Tanwar R, Kar Mahapatra D, Lohan N, Dahiya G, Jain D. Assessment of Blockchain Technology in the Improvement of Supply Chain Management in the Pharmaceutical Industry. *Recent patents on biotechnology*. 2025.
98. Li Z, Yin S, Feng J, Gao X, Yang Q, Zhu F. Acupuncture combined with Chinese herbal medicine in the treatment of perimenopausal insomnia: A systematic review and meta-analysis. *Medicine*. 2023;102(45):e35942.
99. Porceddu SV, Daniels C, Yom SS, Liu H, Waldron J, Gregoire V, et al. Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN). *International journal of radiation oncology, biology, physics*. 2020;107(4):641-51.
100. Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2018;126(1):3-24.
101. Gordon M, Nigam GB, Sinopoulou V, Al Bakir I, Bateman AC, Din S, et al. Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease. *BMJ open gastroenterology*. 2024;11(1).
102. Lutgens M, van Oijen M, Mooiweer E, van der Valk M, Vleggaar F, Siersema P, et al. A risk-profiling approach for surveillance of inflammatory bowel disease-colorectal carcinoma is more cost-effective: a comparative cost-effectiveness analysis between international guidelines. *Gastrointestinal endoscopy*. 2014;80(5):842-8.
103. Harris C, Allen K, Ramsey W, King R, Green S. Sustainability in Health care by Allocating Resources Effectively (SHARE) 11: reporting outcomes of an evidence-driven approach to disinvestment in a local healthcare setting. *BMC health services research*. 2018;18(1):386.
104. Harris C, Allen K, Brooke V, Dyer T, Waller C, King R, et al. Sustainability in Health care by Allocating Resources Effectively (SHARE) 6: investigating methods to identify, prioritise, implement and evaluate disinvestment projects in a local healthcare setting. *BMC health services research*. 2017;17(1):370.
105. Walsh-Bailey C, Tsai E, Tabak RG, Morshed AB, Norton WE, McKay VR, et al. A scoping review of de-implementation frameworks and models. *Implementation science : IS*. 2021;16(1):100